Aethlon Medical Inc (AEMD) Stock AnalysisAEMDStock AnalysisAethlon Medical Inc

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Aethlon Medical Inc is not a good buy right now due to its significant financial losses and poor performance metrics. The current price is $2.49, with a year-to-date change of -82.34%, indicating a severe decline in value. Additionally, the company reported a net loss of $1.55 million for Q1 2026, which is a slight improvement but still reflects ongoing financial struggles. The main risk is its high forward P/E ratio of 0.2074, which suggests that investors are not confident in future profitability. Overall, the combination of negative performance trends and financial instability makes this stock a sell.

1 analysts cover AEMD: 1 rate it Buy, 0 Hold and 0 Sell.